ArticleClinical ophthalmology (Auckland, N.Z.)2019
TearCare
Article in Clinical ophthalmology (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial.Optometry and vision science : official publication of the American Academy of Optometry · 2025Trial
- Improved Signs and Symptoms of Dry Eye Disease for RestasisClinical ophthalmology (Auckland, N.Z.) · 2024Trial
- A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCareClinical ophthalmology (Auckland, N.Z.) · 2020Trial
- Comparison of manual versus automated thermal lid therapy with expression for meibomian gland dysfunction in patients with dry eye disease.Scientific reports · 2024Article
- Meibomian Gland Dysfunction Clinical Practice Guidelines.Japanese journal of ophthalmology · 2023Article
- Solving STODS-Surgical Temporary Ocular Discomfort Syndrome.Diagnostics (Basel, Switzerland) · 2023Review
- Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy.Clinical optometry · 2022Review
- A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Smart contact lens and transparent heat patch for remote monitoring and therapy of chronic ocular surface inflammation using mobiles.Science advances · 2021Article
- Therapeutic Instruments Targeting Meibomian Gland Dysfunction.Ophthalmology and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvaluation of the safety and effectiveness of a TearCare PATIENTS AND
methodsThis was an extension of an initial 6-month, prospective, single-center, randomized, parallel-group pilot study. In the initial study, subjects with DED were randomized to either a single TearCare
resultsTwelve subjects participated in the 6-month extension study. At 1-month clinic visit following retreatment, a significant improvement from baseline in mean (± SD) TBUT of 12.4 (±3.3) seconds was observed (
conclusionThe findings of the extension study through 12 months suggest that a second TearCare
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.